

JUBILANT DRUG DEVELOPMENT PTE LTD.
Balance Sheet

As at 31st Mar	Notes No	2014		2013	
		USD	INR (' In Thousands)	USD	INR (' In Thousands)
I. EQUITY AND LIABILITIES					
Shareholders' Funds					
Share capital	1	2,547,001	127,332	2,527,001	126,258
Reserves & surplus	2	(61,728)	21,560	(49,326)	8,255
Money received against share warrants				-	
		2,485,273	148,893	2,477,675	134,513
Current liabilities					
Trade payables	3	4,722	283	-	-
Other current liabilities	4	159	10	6,329	344
		4,881	292	6,329	344
		2,490,154	149,185	2,484,004	134,857
II. ASSETS					
Non-current investments					
Non-current investments	5	2,478,416	148,482	2,478,416	134,553
Long-term loans and advances	6	3,971	238	4,026	219
		2,482,387	148,720	2,482,442	134,772
Current assets					
Cash & bank balances	7	7,767	465	1,562	85
		7,767	465	1,562	85
Total		2,490,154	149,185	2,484,004	134,857

Rajneesh Gupta
Head Accounts
Place : Noida
Date : 22nd May 2014

JUBILANT DRUG DEVELOPMENT PTE LTD.
Statement of Profit and Loss

For the year ended 31st March,	Notes No	2014	2014	2013	2013
		USD	INR (' In Thousands)	USD	INR (' In Thousands)
EXPENSES					
Other expenses	8	12,348	746	12,040	654
Total expenses		12,348	746	12,040	654
Profit before exceptional items and tax		(12,348)	(746)	(12,040)	(654)
Exceptional items	9	54	3	(48)	(3)
Profit for the Year		(12,402)	(750)	(11,992)	(652)

Rajneesh Gupta
Head Accounts
Place : Noida
Date : 22nd May 2014

JUBILANT DRUG DEVELOPMENT PTE LTD**CASH FLOW STATEMENT**

For the year ended 31st March,

	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
A. Cash flows from operating activities				
Net income before minority interest	(12,402)	(750)	(11,992)	(652)
<i>Adjustments to reconcile net income to net cash provided by operating activities</i>				
Unrealised (gain)/loss on exchange (including mark-to-market on currency and interest rate swaps)	-	-	(48)	(3)
	-	-	(48)	(3)
Operating profit before working capital changes	(12,402)	(750)	(12,040)	(654)
Adjustments for :				
(Increase)/Decrease in trade and other receivables	54	3	3,463	188
Increase/(Decrease) in trade and other payables	(1,448)	(87)	2,513	137
Net cash inflow/(outflow) in course of operating activities	(13,796)	(834)	(6,064)	(330)
B. Cash flow arising from financing activities :				
Proceeds from issue of share capital(including share premium & net of share issue expenses)	20,000	1,208	7,000	380
Net cash inflow/(outflow) in course of financing activities	20,000	1,208	7,000	380
C. Foreign currency translation difference arising on consolidation				
		6		2
Net Increase in cash & cash equivalents (A+B+C)	6,205	380	936	53
Add: cash & cash equivalents at the beginning of year(including balance in dividend accounts)	1,562	85	627	32
Cash & cash equivalents at the close of the year(including balance in dividend accounts)	7,767	465	1,562	85

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".

Rajneesh Gupta

Head Accounts

Place : Noida

Date : 22nd May, 2014

JUBILANT DRUG DEVELOPMENT PTE LTD.

Notes to the Financial Statements

As at 31st Mar	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
1. SHARE CAPITAL				
Authorized				
Equity Share Capital	-	-	-	-
Issued & Subscribed				
2,547,001 equity shares of USD 1 each	-	-	-	-
(Previous Year 2,527,001 equity shares of USD 1 each)	-	-	-	-
Paid up				
2,547,001 equity shares of USD 1 each	2,547,001	127,332	2,527,001	126,258
(Previous Year 2,527,001 equity shares of USD 1 each)				
	2,547,001	127,332	2,527,001	126,258

1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.

2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential

3) The details of shareholders holding more than 5% shares in the company :

As at 31st Mar	2014	2014	2013	2013
Name of the shareholder	No of shares	% held	No of shares	% held
Jubilant Life Sciences (BVI) Ltd - the Holding Company	2,547,001	100%	2,527,001	100%

4) The reconciliations of number of shares outstanding at beginning and at the end of reporting period

As at 31st Mar	2014	2014	2013	2013
Particulars	No	INR (' In Thousands)	No	INR (' In Thousands)
Numbers of shares at the beginning	2,527,001	126,258	2,520,001	125,868
Add: Shares issued during the year	20,000	1,074	7,000	390
Numbers of shares at the end	2,547,001	127,332	2,527,001	126,258

5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

As at 31st Mar	2014	2014	2013	2013
Particulars	No	INR (' In Thousands)	No	INR (' In Thousands)
Jubilant Life Sciences (BVI) Ltd., British Virgin Islands - the Holding Company	2,547,001	127,332	2,527,001	126,258
2,547,001 equity shares of USD 1 each				
(Previous Year 2,527,001 equity shares of USD 1 each)				

JUBILANT DRUG DEVELOPMENT PTE LTD.
Notes to the Financial Statements

As at 31st Mar	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
2. RESERVES AND SURPLUS				
Foreign Currency Translation Reserve				
Foreign Currency Translation Reserve Opening	-	10,647	-	8,469
Foreign Currency Translation Reserve During the Year	-	14,055	-	10,647
	-	24,702	-	10,647
Surplus as per P&L Account				
As per last Balance Sheet	(49,326)	(2,392)	(37,334)	(1,741)
Add: Net Profit after tax transferred from Statement of Profit and Loss	(12,402)	(750)	(11,992)	(652)
	(61,728)	21,560	(49,326)	8,255
3. TRADE PAYABLES				
Trade payables-others	4,722	283	-	-
	4,722	283	-	-
4. OTHER CURRENT LIABILITIES				
Other payables	159	10	6,329	344
	159	10	6,329	344
5. NON-CURRENT INVESTMENTS				
Investment in Subsidiary/ Fellow subsidiaries Companies				
Jubilant Chemsys Limited	2,076,349	124,394	2,076,349	112,725
1,999,766 shares (previous year 1,999,766 shares) of Rs. 10 each				
Jubilant Clinsys Limited	402,067	24,088	402,067	21,828
1,999,766 shares (previous year 1,999,766 shares) of Rs. 10 each				
	2,478,416	148,482	2,478,416	134,553
6. LONG TERM LOANS AND ADVANCES				
Security deposits(unsecured, considered good)	3,971	238	4,026	219
	3,971	238	4,026	219
7. CASH AND BANK BALANCES				
Cash and cash equivalents				
Balances with banks:				
- On current accounts	7,767	465	1,562	85
	7,767	465	1,562	85
8. OTHER EXPENSE				
Auditors Remuneration - As Auditors	3,824	231	4,149	225
Legal , professional & consultancy charges	8,224	497	7,317	398
Directors' sitting fees	159	10	474	26
Bank Charges	140	8	100	5
	12,348	746	12,040	654
9. EXCEPTIONAL ITEMS				
Foreign Exchange Gain/Loss	54	3	(48)	(3)
	54	3	(48)	(3)